News & Updates

Show Multimedia Only
Brolucizumab for neovascular age-related macular degeneration holds up in real world

Brolucizumab for neovascular age-related macular degeneration holds up in real world

30 Sep 2022

The use of brolucizumab for the treatment of patients with neovascular age-related macular degeneration (nAMD) in the real-world setting appears to be effective and safe, consistent with data from pivotal trials, as reported in a study.

30 Sep 2022
SGLT2 inhibitors potentially protective against dry eye disease SGLT2 inhibitors potentially protective against dry eye disease

SGLT2 inhibitors potentially protective against dry eye disease

29 Sep 2022 byJairia Dela Cruz

Type 2 diabetes (T2D) patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be at lower risk of dry eye disease (DED) compared with their counterparts who are receiving glucagonlike peptide-1 receptor agonists (GLP-1 RAs), as shown in a study.

29 Sep 2022
Glaucoma risk modestly low in diabetes

Glaucoma risk modestly low in diabetes

04 Sep 2022

Patients with diabetes mellitus are at reduced risk of developing open-angle glaucoma (OAG), although the magnitude of reduction is modest, according to a study.

04 Sep 2022